Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Methods (San Diego, Calif.)|July 23, 2013
Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodiesBrian D Harms, Jeffrey D Kearns, Sergio Iadevaia, et al.
Biophysical Journal|February 17, 2005
Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusionsBrian D Harms, Gina M Bassi, Alan Rick Horwitz, et al.
Methods in Enzymology|January 3, 2012
Optimizing properties of antireceptor antibodies using kinetic computational models and experimentsBrian D Harms, Jeffrey D Kearns, Stephen V Su, et al.
Molecular Cancer Therapeutics|May 9, 2012
Impact of intrinsic affinity on functional binding and biological activity of EGFR antibodiesYu Zhou, Anne-Laure Goenaga, Brian D Harms, et al.
Plos One|October 8, 2013
Lessons learned from quantitative dynamical modeling in systems biologyAndreas Raue, Marcel Schilling, Julie Bachmann, et al.
Molecular Cancer Therapeutics|January 18, 2012
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3Charlotte F McDonagh, Alexandra Huhalov, Brian D Harms, et al.
Molecular Cancer Therapeutics|November 28, 2013
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitorsJonathan B Fitzgerald, Bryan W Johnson, Jason Baum, et al.
Science Signaling|July 2, 2009
Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axisBirgit Schoeberl, Emily A Pace, Jonathan B Fitzgerald, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2019
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAMJessica B Casaletto, Melissa L Geddie, Adnan O Abu-Yousif, et al.
Cancer Research|December 24, 2009
Systems biologists seek fuller integration of systems biology approaches in new cancer research programsOlaf Wolkenhauer, Charles Auffray, Simone Baltrusch, et al.
Pageof 1